Clinical

Articles

With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy

Lifileucel Continues to Show Durable Responses in Advanced Melanoma

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma efficacy results continue to show a durable response. 

Lenvatinib-Pembrolizumab Combo Improves Outcomes in Certain Patients With Advanced Melanoma

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.

Nivolumab Monotherapy, With Ipilimumab Continuously Improves Outcomes in Advanced Melanoma

About 40% of patients who progressed on placebo following resection of melanoma experienced an objective response with crossover to pembrolizumab in the phase 3 EORTC 1325/KEYNOTE-054 trial.

Crossover to Pembrolizumab for Patients With Resected, Stage III Melanoma Yields Better Efficacy Vs Rechallenge

A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting. 

Adding Lifileucel to Pembrolizumab for Immunotherapy-Naïve Melanoma Improved Responses

Progression-free survival more than doubled when relatlimab was added to nivolumab to treated patients with previously untreated, unresectable or metastatic melanoma.

Median PFS Extended in Advanced Melanoma Treated With Frontline Relatlimab/Nivolumab

The study concluded that immune-related adverse events were more common than previously anticipated following adjuvant anti–PD-1 therapy and persisted with prolonged follow-up.

Chronic IRAEs With Adjuvant Anti–PD-1 Therapy More Common Than Previously Understood for Resected Melanoma

Darovasertib as monotherapy for the treatment for patients with heavily pretreated metastatic uveal melanoma induced responses and promising rates of overall survival, according to preliminary data from a phase 1/2 trial.

Phase 1/2 trial of Darovasertib With or Without Binimetinib Is Feasible, Safe for Metastatic Uveal Melanoma

Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.

Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma

The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.

Melanoma | Topics